6-[4-(叔丁基)苯氧基]吡啶-3-胺
| 中文名称 | 6-[4-(叔丁基)苯氧基]吡啶-3-胺 |
|---|---|
| 中文同义词 | 6-[4-(叔丁基)苯氧基]吡啶-3-胺;5-氨基-2-(4-叔丁苯氧基)吡啶;6-[4-(叔丁基)苯氧基]吡啶-3-胺;6-[4-(叔丁基)苯氧基]吡啶-3-胺 6-(4-(tert-Butyl)phenoxy)pyridin-3-amine;6-[4-(叔丁基)苯氧基]吡啶-3-胺6-(4-(TERT-BUTYL)PHENOXY)PYRIDIN-3-AMINE;6-[4-(叔丁基)苯氧基]吡啶-3-胺,10 MM DMSO 溶液;CB-103 |CAS 218457-67-1;218457-67-1;CB-103 |
| 英文名称 | 5-Amino-2-(4-tert-butylphenoxy)pyridine |
| 英文同义词 | 6-[4-(tert-Butyl)phenoxy]pyridin-3-amine 97%;6-[4-(tert-Butyl)phenoxy]pyridin-3-amine97%;6-[4-(TERT-BUTYL)PHENOXY]PYRIDIN-3-AMINE;BUTTPARK 96\12-100;6-(4-tert-butylphenoxy)-3-pyridinamine;3-Pyridinamine, 6-[4-(1,1-dimethylethyl)phenoxy]-;pathway,CB103,inhibit,Inhibitor,Notch,CB-103,signaling,leukemia,CB 103;6-[4-(1,1-Dimethylethyl)phenoxy]-3-pyridinamine |
| CAS号 | 218457-67-1 |
| 分子式 | C15H18N2O |
| 分子量 | 242.32 |
| EINECS号 | |
| 相关类别 | 抑制剂;合成中间体 |
| Mol文件 | 218457-67-1.mol |
| 结构式 | ![6-[4-(叔丁基)苯氧基]吡啶-3-胺 结构式](CAS/GIF/218457-67-1.gif) |
6-[4-(叔丁基)苯氧基]吡啶-3-胺 性质
| 熔点 | 89-90 |
|---|---|
| 储存条件 | 2-8°C |
| 溶解度 | 溶于 DMSO (>30 mg/ml) |
| 形态 | 固体 |
| 颜色 | 灰白色至淡橙色 |
| 稳定性 | 可在-20°C下的DMSO中的溶液储存长达3个月。 |
| InChI | 1S/C15H18N2O/c1-15(2,3)11-4-7-13(8-5-11)18-14-9-6-12(16)10-17-14/h4-10H,16H2,1-3H3 |
| InChIKey | WHIWGRCYMQLLAO-UHFFFAOYSA-N |
| SMILES | Nc1cnc(cc1)Oc2ccc(cc2)C(C)(C)C |
| CAS 数据库 | 218457-67-1(CAS DataBase Reference) |
CB-103 是一种口服活性的 Notch 转录激活复合物的抑制剂。CB-103 可在果蝇和小鼠中产生Notch功能丧失的表型，并抑制人类乳腺癌和白血病异种移植瘤的生长。
| Target | Value |
|
Notch
() |
CB-103 acts as a pan-NOTCH inhibitor by targeting NOTCH transcriptional activation complex.
CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines.
CB-103 exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines.
Cell Viability Assay
| Cell Line: | RPMI 8402, KOPTK1, PANC1, nRas driven melanoma cells |
| Concentration: | 10 μM |
| Incubation Time: | 4 days, 6 days |
| Result: | Caused a significant reduction in their growth potential. |
CB-103 inhibits NOTCH dependent cellular processes in mice.
CB-103 blocks in vivo growth of PDX models of T-ALL.
CB-103 (25 mg/kg; i.p./p.o.; 2x daily; for 2 weeks) inhibits growth of GSI/Mab resistant triple negative breast cancer.
CB-103 exhibits anti-tumor activity in xenograft models of human T-ALL and mouse mammary tumors.
| Animal Model: | NSG mice, triple negative breast cancer mouse xenograft model |
| Dosage: | 25 mg/kg |
| Administration: | Oral administration/Intraperitoneal injection; 2x daily; for 2 weeks |
| Result: | Inhibited growth of GSI/Mab resistant triple negative breast cancer. |
安全信息
| 危险品标志 | Xi |
|---|---|
| WGK Germany | WGK 3 |
| Hazard Note | Irritant |
| 海关编码 | 2933399990 |
| 存储类别 | 11 - 可燃固体 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/09/15 | HY-135145 | 6-[4-(叔丁基)苯氧基]吡啶-3-胺 Limantrafin | 218457-67-1 | 10 mg | 298元 |
| 2026/09/15 | HY-135145 | 6-[4-(叔丁基)苯氧基]吡啶-3-胺 Limantrafin | 218457-67-1 | 10 mM * 1 mLin DMSO | 327元 |